Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
about
Biomarkers for depression: recent insights, current challenges and future prospects.Repeated salivary daytime cortisol and onset of mood episodes in offspring of bipolar parents.Backing into the future: pharmacological approaches to the management of resistant depressionGrey and white matter differences in Chronic Fatigue Syndrome - A voxel-based morphometry study
P2860
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Antidepressant augmentation wi ...... sed, placebo-controlled trial.
@en
Antidepressant augmentation wi ...... sed, placebo-controlled trial.
@nl
type
label
Antidepressant augmentation wi ...... sed, placebo-controlled trial.
@en
Antidepressant augmentation wi ...... sed, placebo-controlled trial.
@nl
prefLabel
Antidepressant augmentation wi ...... sed, placebo-controlled trial.
@en
Antidepressant augmentation wi ...... sed, placebo-controlled trial.
@nl
P2093
P50
P1476
Antidepressant augmentation wi ...... ised, placebo-controlled trial
@en
P2093
ADD Study Team
Adrian J Lloyd
Baxi N P Sinha
Chrysovalanto Mamasoula
Fiona H Winter
I Nicol Ferrier
June Wainwright
Nick Steen
Peter M Haddad
Tom Hughes
P304
P356
10.1016/S2215-0366(15)00436-8
P50
P577
2015-12-23T00:00:00Z